clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2025-103-8-9-670-676clinmed-1271Research ArticleЗАМЕТКИ И НАБЛЮДЕНИЯ ИЗ ПРАКТИКИNOTES AND OBSERVATIONS FROM PRACTICEАритмогенная кардиомиопатия индуцированная тахисистолической фибрилляцией предсердийArrhythmogenic cardiomyopathy as a complication of tachysystolic atrial fibrillationhttps://orcid.org/0009-0001-1756-9821ЗавалишинаТ. В.ZawalishinaT. V.

Завалишина Татьяна Владимировна — врач функциональной диагностики

Москва

Tatyana V. Zawalishina — doctor of functional diagnostics 

Moscow 

tzawalishina@yandex.ruhttps://orcid.org/0000-0001-6056-835XМатвееваМ. Г.MatveevaM. G.

Матвеева Марина Георгиевна — канд. мед. наук, врач функциональной диагностики

Москва

Marina G. Matveeva — Candidate of Medical Sciences, doctor of functional diagnostics

Moscow 

https://orcid.org/0000-0001-8830-7231ЛомакинН. В.LomakinN. V.

Ломакин Никита Валерьевич — д-р мед. наук, профессор, заведующий кардиологическим отделением №2

Москва

Nikita V. Lomakin — Doctor of Medical Sciences, Professor, head of Cardiology Department №2

Moscow 

https://orcid.org/0000-0002-9725-7528АлехинМ. Н.AlekhinM. N.

Алехин Михаил Николаевич — д-р мед. наук, профессор, заведующий отделением функциональной диагностики

Москва

Mikhail N. Alekhin — Doctor of Medical Sciences, Professor, functional diagnostics

Moscow 

ФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента Российской ФедерацииРоссияCentral Clinical Hospital with Outpatient Clinic of Department of Presidential AffairsRussian Federation2025270120261038-9670676Copyright © Завалишина Т.В., Матвеева М.Г., Ломакин Н.В., Алехин М.Н., 20262026Завалишина Т.В., Матвеева М.Г., Ломакин Н.В., Алехин М.Н.Zawalishina T.V., Matveeva M.G., Lomakin N.V., Alekhin M.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/1271

В статье представлен клинический случай сложного в диагностическом плане заболевания — аритмогенной кардиомиопатии у пациента с пароксизмальной формой фибрилляции предсердий. Сложность этого диагноза обусловлена тем, что его можно поставить только ретроспективно, когда после успешного контроля ритма, включая кардиоверсию или абляцию, восстанавливается систолическая функция левого желудочка и уходит клиническая симптоматика. Рассмотрены вопросы распространенности заболевания и его место в современной классификации кардиомиопатий. Отмечены особенности структурных, функциональных и гемодинамических изменений в сердце. Обсуждаются современные подходы к диагностике заболевания и выбора эффективной стратегии лечения.

The article presents a clinical case of a diagnostically difficult disease – arrhythmogenic cardiomyopathy in a patient with paroxysmal atrial fibrillation. The complexity of this diagnosis is due to the fact that it can only be made retrospectively, when after successful rhythm control, including cardioversion or ablation, the systolic function of the left ventricle is restored and clinical symptoms disappear. The issues of the prevalence of the disease and its place in the modern classification of cardiomyopathies are considered. The features of structural, functional and hemodynamic changes in the heart are noted. Modern approaches to the diagnosis of the disease and the choice of an effective treatment strategy are discussed.

аритмогенная кардиомиопатияфибрилляция предсердийнедилатационная кардиомиопатия левого желудочкаэхокардиографияarrhythmogenic cardiomyopathyatrial fibrillationnon-dilated left ventricular cardiomyopathyechocardiographyReferencesVan Gelder I.C., Rienstra M., Bunting, K.V., Casado-Arroyo R., Caso V., Crijns H.J.G.M.et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2024;45(36):3314–3414. http://doi:10.1093/eurheartj/ehae176Van Gelder I.C., Rienstra M., Bunting, K.V., Casado-Arroyo R., Caso V., Crijns H.J.G.M.et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2024;45(36):3314–3414. http://doi:10.1093/eurheartj/ehae176Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., Голицын С.П., Голухова Е.З., Горев М.В.и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. DOI: 10.15829/1560-4071-2021-4594Arakelyan M.G., Bokeria L.A., Vasilyeva E.Yu., Golitsyn S.P., Golukhova E.Z., Gorev M.V. et al. Atrial fibrillation and flutter. Clinical guidelines 2020. Russian Journal of Cardiology. 2021;26(7):4594. (In Russian). DOI: 10.15829/1560-4071-2021-4594Ulus T., Okyay K., Kabul HK. et al. Turkish Society of Cardiology consensus paper on management of arrhythmia-induced cardiomyopathy. Anatol. J. Cardiol. 2019;21(2):98–106. DOI: 10.14744/AnatolJCardiol.2019.60687Ulus T., Okyay K., Kabul HK. et al. Turkish Society of Cardiology consensus paper on management of arrhythmia-induced cardiomyopathy. Anatol. J. Cardiol. 2019;21(2):98–106. DOI: 10.14744/AnatolJCardiol.2019.60687Huizar J.F., Ellenbogen K.A., Tan A.Y., Kaszala K. Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2019;73(18):2328–2344. DOI: 10.1016/j.jacc.2019.02.045Huizar J.F., Ellenbogen K.A., Tan A.Y., Kaszala K. ArrhythmiaInduced Cardiomyopathy: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2019;73(18):2328–2344. DOI: 10.1016/j.jacc.2019.02.045Soliman E.Z., Safford M.M., Muntner P., Khodneva Y., Dawood F.Z., Zakai N.A.et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern. Med. 2014;174(1):107–14. DOI: 10.1001/jamainternmed.2013.11912Soliman E.Z., Safford M.M., Muntner P., Khodneva Y., Dawood F.Z., Zakai N.A.et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern. Med. 2014;174(1):107–14. DOI: 10.1001/jamainternmed.2013.11912Qin D., Mansour M.C., Ruskin J.N., Heist E.K. Atrial fibrillationmediated cardiomyopathy. Circ. Arrhythm. Electrophysiol. 2019;12(12):e007809. DOI: 10.1161/CIRCEP.119.007809Qin D., Mansour M.C., Ruskin J.N., Heist E.K. Atrial fibrillationmediated cardiomyopathy. Circ. Arrhythm. Electrophysiol. 2019;12(12):e007809. DOI: 10.1161/CIRCEP.119.007809Raymond-Paquin A., Nattel S., Wakili R., Tadros R. Mechanisms and clinical significance of arrhythmia-induced cardiomyopathy. Can. J. Cardiol. 2018;34(11):1449–1460. DOI: 10.1016/j.cjca.2018.07.475Raymond-Paquin A., Nattel S., Wakili R., Tadros R. Mechanisms and clinical significance of arrhythmia-induced cardiomyopathy. Can. J. Cardiol. 2018;34(11):1449–1460. DOI: 10.1016/j.cjca.2018.07.475González-Ferrero T., Bergonti M., López-Canoa J.N., Arias F.G., Eiras Penas S., Spera F.et al. Atrial fibrillation ablation in patients with arrhythmia-induced cardiomyopathy: a prospective multicentre study. ESC Heart Fail. 2023;10(5):3055–3066. DOI: 10.1002/ehf2.14448González-Ferrero T., Bergonti M., López-Canoa J.N., Arias F.G., Eiras Penas S., Spera F.et al. Atrial fibrillation ablation in patients with arrhythmia-induced cardiomyopathy: a prospective multicentre study. ESC Heart Fail. 2023;10(5):3055–3066. DOI: 10.1002/ehf2.14448Serban T., Badertscher P., du Fay de Lavallaz J. et al. Definition and management of arrhythmia-induced cardiomyopathy: findings from the European Heart Rhythm Association survey. Europace. 2024;26(5):euae112. DOI: 10.1093/europace/euae112Serban T., Badertscher P., du Fay de Lavallaz J. et al. Definition and management of arrhythmia-induced cardiomyopathy: findings from the European Heart Rhythm Association survey. Europace. 2024;26(5):euae112. DOI: 10.1093/europace/euae112Towbin J.A., McKenna W.J., Abrams D.J. et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm. 2019;16(11):e373–e407. DOI: 10.1016/j.hrthm.2019.09.019Towbin J.A., McKenna W.J., Abrams D.J. et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm. 2019;16(11):e373–e407. DOI: 10.1016/j.hrthm.2019.09.019Arbelo E., Protonotarios A., Gimeno J.R., Arbustini E., Barriales-Villa R. et al., ESC Scientific Document Group (2023). 2023 ESC Guidelines for the management of cardiomyopathies. European Heart Journal. 2023;44(37):3503–3626. DOI: 10.1093/eurheartj/ehad194Arbelo E., Protonotarios A., Gimeno J.R., Arbustini E., BarrialesVilla R. et al., ESC Scientific Document Group (2023). 2023 ESC Guidelines for the management of cardiomyopathies. European Heart Journal. 2023;44(37):3503–3626. DOI: 10.1093/eurheartj/ehad194Eda Y., Nabeta T., Iikura S., Takigami Y., Fujita T., Iida Y. et al. Nondilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes. ESC Heart Fail. 2024;11(3):1463– 1471. DOI: 10.1002/ehf2.14711Eda Y., Nabeta T., Iikura S., Takigami Y., Fujita T., Iida Y. et al. Nondilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes. ESC Heart Fail. 2024;11(3):1463– 1471. DOI: 10.1002/ehf2.14711Khan M.N., Jaïs P., Cummings J., Di Biase L., Sanders P., Martin D.O. et al. PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N. Engl. J. Med. 2008;359:1778–1785. DOI: 10.1056/NEJMoa0708234Khan M.N., Jaïs P., Cummings J., Di Biase L., Sanders P., Martin D.O. et al. PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N. Engl. J. Med. 2008;359:1778–1785. DOI: 10.1056/NEJMoa0708234Prabhu S., Taylor A.J., Costello B.T., Kaye D.M., McLellan A. J.A.et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI Study. Journal of the American College of Cardiology. 2017;70(16):1949–1961. DOI: 10.1016/j.jacc.2017.08.041Prabhu S., Taylor A.J., Costello B.T., Kaye D.M., McLellan A. J.A.et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI Study. Journal of the American College of Cardiology. 2017;70(16):1949–1961. DOI: 10.1016/j.jacc.2017.08.041Pandey A., Kim S., Moore C., Thomas L., Gersh B., Allen L.A. et al. ORBIT-AF Investigators and Patients. Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation. JACC Heart Fail. 2017;5:44–52. DOI: 10.1016/j.jchf.2016.09.016Pandey A., Kim S., Moore C., Thomas L., Gersh B., Allen L.A. et al. ORBIT-AF Investigators and Patients. Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation. JACC Heart Fail. 2017;5:44–52. DOI: 10.1016/j.jchf.2016.09.016Zeppenfeld K., Tfelt-Hansen J., de Riva M., Winkel B.G., Behr E.R., Blom N.A.et al., ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2022;43(40):3997–4126. DOI: 10.1093/eurheartj/ehac262Zeppenfeld K., Tfelt-Hansen J., de Riva M., Winkel B.G., Behr E.R., Blom N.A.et al., ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2022;43(40):3997–4126. DOI: 10.1093/eurheartj/ehac262Gentl esk P.J., Sauer W.H., Gerstenfeld E.P., Lin D., Dixit S., Zado E., Callans D., Marchlinski F.E. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J. Cardiovasc. Electrophysiol. 2007;18:9–14. DOI: 10.1111/j.1540-8167.2006.00653.xGentl esk P.J., Sauer W.H., Gerstenfeld E.P., Lin D., Dixit S., Zado E., Callans D., Marchlinski F.E. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J. Cardiovasc. Electrophysiol. 2007;18:9–14. DOI: 10.1111/j.1540-8167.2006.00653.xNakano Y., Ochi H., Sairaku A., Onohara Y., Tokuyama T., Motoda C. et al. HCN4 Gene Polymorphisms Are Associated With Occurrence of Tachycardia-Induced Cardiomyopathy in Patients With Atrial Fibrillation. Circ. Genom Precis. Med. 2018;11(7):e001980. DOI: 10.1161/CIRCGEN.117.001980Nakano Y., Ochi H., Sairaku A., Onohara Y., Tokuyama T., Motoda C. et al. HCN4 Gene Polymorphisms Are Associated With Occurrence of Tachycardia-Induced Cardiomyopathy in Patients With Atrial Fibrillation. Circ. Genom Precis. Med. 2018;11(7):e001980. DOI: 10.1161/CIRCGEN.117.001980Deshmukh P.M., Krishnamani R., Romanyshyn M., Johnson A.K., Noti J.D. Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. International journal of molecular medicine. 2004;13(3):455–458. DOI: 10.3892/ijmm.13.3.455Deshmukh P.M., Krishnamani R., Romanyshyn M., Johnson A.K., Noti J.D. Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. International journal of molecular medicine. 2004;13(3):455–458. DOI: 10.3892/ijmm.13.3.455Gopinathannair R., Etheridge S.P., Marchlinski F.E., Spinale F.G., Lakkireddy D., Olshansky B. Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J. Am. Coll. Cardiol. 2015;66(15):1714–1728. DOI: 10.1016/j.jacc.2015.08.038Gopinathannair R., Etheridge S.P., Marchlinski F.E., Spinale F.G., Lakkireddy D., Olshansky B. Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J. Am. Coll. Cardiol. 2015;66(15):1714–1728. DOI: 10.1016/j.jacc.2015.08.038Shantsila E., Shantsila A., Blann A.D., Lip G.Y. Am. J. Cardiol. 2013;111:996–1001. DOI: 10.1016/j.amjcard.2012.12.005Shantsila E., Shantsila A., Blann A.D., Lip G.Y. Am. J. Cardiol. 2013;111:996–1001. DOI: 10.1016/j.amjcard.2012.12.005Korthals D., Eckardt L. The new European Society of Cardiology guideline for the management of cardiomyopathies: key messages for cardiac electrophysiologists. Herzschrittmacherther Elektrophysiol. 2023;34(4):311–323. DOI: 10.1007/s00399-023-00975-yKorthals D., Eckardt L. The new European Society of Cardiology guideline for the management of cardiomyopathies: key messages for cardiac electrophysiologists. Herzschrittmacherther Elektrophysiol. 2023;34(4):311–323. DOI: 10.1007/s00399-023-00975-yGoette A., Kalman J.M., Aguinaga L., Akar J., Cabrera J.A., Chen S.A. et al. Document Reviewers: (2016). EHRA/HRS/APHRS/ SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. Europace. 2016;18(10):1455–1490. DOI: 10.1093/europace/euw161Goette A., Kalman J.M., Aguinaga L., Akar J., Cabrera J.A., Chen S.A. et al. Document Reviewers: (2016). EHRA/HRS/APHRS/ SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. Europace. 2016;18(10):1455–1490. DOI: 10.1093/europace/euw161Nia A.M., Gassanov N., Dahlem K.M., Caglayan E., Hellmich M., Erdmann E., Er F. Diagnostic accuracy of NT-proBNP ratio (BNP-R) for early diagnosis of tachycardia-mediated cardiomyopathy: a pilot study. Clin. Res. Cardiol. 2011;100:887–896. DOI: 10.1007/s00392-011-0319-yNia A.M., Gassanov N., Dahlem K.M., Caglayan E., Hellmich M., Erdmann E., Er F. Diagnostic accuracy of NT-proBNP ratio (BNP-R) for early diagnosis of tachycardia-mediated cardiomyopathy: a pilot study. Clin. Res. Cardiol. 2011;100:887–896. DOI: 10.1007/s00392-011-0319-yDi Biase L., Mohanty P., Mohanty S., et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016;133(17):1637–1644. DOI: 10.1161/CIRCULATIONAHA.115.019406Di Biase L., Mohanty P., Mohanty S., et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016;133(17):1637–1644. DOI: 10.1161/CIRCULATIONAHA.115.019406Marrouche N. F., Brachmann J., Andresen D., Siebels J., Boersma L., Jordaens L.et al. CASTLE-AF Investigators (2018). Catheter ablation for atrial fibrillation with heart failure. The New England journal of medicine. 2018;378(5):417–427. DOI: 10.1056/NEJMoa1707855Marrouche N. F., Brachmann J., Andresen D., Siebels J., Boersma L., Jordaens L.et al. CASTLE-AF Investigators (2018). Catheter ablation for atrial fibrillation with heart failure. The New England journal of medicine. 2018;378(5):417–427. DOI: 10.1056/NEJMoa1707855Watanabe H., Okamura K., Chinushi M., Furushima H., Tanabe Y., Kodama M., Aizawa Y. Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. International heart journal. 2008;49(1):9–47. DOI: 10.1536/ihj.49.39Watanabe H., Okamura K., Chinushi M., Furushima H., Tanabe Y., Kodama M., Aizawa Y. Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. International heart journal. 2008;49(1):9–47. DOI: 10.1536/ihj.49.39Ju W., Yang B., Li M., Zhang F., Chen H., Gu K. et al. Tachycardiomyopathy complicated by focal atrial tachycardia: incidence, risk factors, and long-term outcome. J. Cardiovasc. Electrophysiol. 2014;25(9):953–957. DOI: 10.1111/jce.12428Ju W., Yang B., Li M., Zhang F., Chen H., Gu K. et al. Tachycardiomyopathy complicated by focal atrial tachycardia: incidence, risk factors, and long-term outcome. J. Cardiovasc. Electrophysiol. 2014;25(9):953–957. DOI: 10.1111/jce.12428Ling L.H., Kalman J.M., Ellims A.H., Iles L.M., Medi C., Sherratt C.et al. Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation. Circ. Arrhythm. Electrophysiol. 2013;6(4):697–704. DOI: 10.1161/CIRCEP.113.000681Ling L.H., Kalman J.M., Ellims A.H., Iles L.M., Medi C., Sherratt C.et al. Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation. Circ. Arrhythm. Electrophysiol. 2013;6(4):697–704. DOI: 10.1161/CIRCEP.113.000681

The authors declare that there are no conflicts of interest present.